Investigation Report on China’s Sitagliptin Market 2021-2025

$2,600$3,900

In 2020, due to the impact of the COVID-19 epidemic, the growth rate of Sitagliptin sales fell, but the sale value of Sitagliptin reached CNY389.69 million.

Clear

Description

Sitagliptin is the world’s first listed oral dipeptidyl peptidase-4 (DPP-4) inhibitor, developed by Merck Sharp & Dohme Ltd (JANUVIA). It was approved by the U.S. FDA in October 2006 to be used as a single drug or combination with metformin and thiazolidinedione drugs to improve blood sugar control in type II diabetes. In April 2007, a combination of Sitagliptin and metformin was approved in the United States; in September 2009, the CFDA approved Sitagliptin to enter the Chinese market; in July 2012, the CFDA approved the registration of its combination in China. By 2020, Merck Sharp & Dohme Ltd is the only manufacturers in the Sitagliptin market in China.

According to CRI’s market research, Sitagliptin’s sales in the Chinese market have increased year by year. Sitagliptin was included in the medical insurance reimbursement catalog in 2017, so the sales value of China’s Sitagliptin growth in 2018 was the most obvious, rising from CNY116.98 million in 2017 to CNY233.37 million in 2018, with an annual growth rate of 99.50%. In 2020, due to the impact of the COVID-19 epidemic, the growth rate of Sitagliptin sales fell, but the sale value of Sitagliptin reached CNY389.69 million. The CAGR of Sitagliptin’s sales value in the Chinese market from 2016 to 2020 is 47.44%.

CRI expects that its sales will continue to grow from 2021 to 2025 as the effective alleviation of the COVID-19 epidemic. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. successfully won the first domestic imitation of Sitagliptin after the approval in 2020 and became the fourth domestically-made DPP-4 inhibitor drug. The patent of Sitagliptin will expire in 2022. In the future, its manufacturers will gradually increase, the market will continue to expand, and prices will have a downward trend, which will lead to an increase in Sitagliptin sales and sales volume. Compared with traditional hypoglycemic drugs, sitagliptin does not increase the risk of hypoglycemia and affects weight Neutrality, good cardiovascular safety, and other advantages. Based on these advantages, Sitagliptin ranks first in the DPP-4 inhibitor market. In addition, the huge patient population. The huge patient population will enable the Sitagliptin market to continue to expand. Therefore, Sitagliptin sales will continue to grow from 2021 to 2025 as the market expands.

Topics Covered:
-The impact of COVID-19 on China’s Sitagliptin market
– Sales value of China’s Sitagliptin 2016-2020
– Competitive landscape of China’s Sitagliptin market
– Prices of Sitagliptin in China
– Prices of Sitagliptin in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Sitagliptin market
– Prospect of China’s Sitagliptin market from 2021 to 2025

Additional information

Publisher

Date Published

Pages

Charts

Format

Table of Contents

1 Relevant Concepts of Sitagliptin
1.1 Indications for Sitagliptin
1.2 Development of Sitagliptin in China
1.3 Governmental Approval of Sitagliptin in China
1.4 The Impact of COVID-19 on Sitagliptin sales in China

2 Sales of Sitagliptin in China, 2016-2020
2.1 Sales Value of Sitagliptin
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Sitagliptin
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Sitagliptin by Dosage Form in China, 2016-2020
2.3.1 Tablets
2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Sitagliptin Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Sitagliptin Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Merck Sharp & Dohme Ltd
3.2.1 Enterprise Profile
3.2.2 Sales of JANUVIA (Merck Sharp & Dohme Ltd’s Sitagliptin) in China

4 Prices of Sitagliptin for Different Manufacturers in China, 2020-2021
4.1 Merck Sharp & Dohme Ltd (JANUVIA)
4.2 Analysis of Other Enterprises

5 Prospect of Chinese Sitagliptin drug Market, 2021-2025
5.1 Influential Factors of Chinese Sitagliptin Market Development
5.1.1 The Impact of COVID-19 on Chinese Sitagliptin Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

List of Charts
Chart Patent Information About Sitagliptin Tablets Registration in China
Chart Sales Value of Sitagliptin Tablets over the World
Chart Sales Value of Sitagliptin Tablets in China, 2016-2020
Chart Sales Value of Sitagliptin Tablets in China by Region, 2016-2020
Chart Sales Volume of Sitagliptin Tablets in China, 2016-2020
Chart Sales Volume of Sitagliptin Tablets in China by Region, 2016-2020
Chart Market Share by Sales Value of Top Sitagliptin Manufacturers in China, 2016-2020
Chart Sales Value and Volume of JANUVIA in China, 2016-2020
Chart Referential Prices of JANUVIA in China, 2020-2021
Chart Forecast on Sales Value of Sitagliptin in China, 2021-2025
Chart Forecast on Sales Volume of Sitagliptin in China, 2021-2025